肝癌TACE还是HAIC?  

Treatment of hepatocellular carcinoma:TACE or HAIC?

作　　者：杜楠 王英[1,2] 李文涛 DU Nan;WANG Ying;LI Wentao(Department of Interventional Radiology,Affiliated Cancer Hospital of Fudan University,Department of Oncology,Shanghai Medical College of Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院介入治疗科,上海200032 [2]复旦大学上海医学院肿瘤学系,上海200032

出　　处：《介入放射学杂志》2024年第12期1269-1273,共5页Journal of Interventional Radiology

摘　　要：经导管动脉化疗栓塞术(TACE)是目前中晚期不可切除肝癌的常用治疗方法。近年来,国内奥沙利铂+氟尿嘧啶+亚叶酸钙(FOLFOX)方案的肝动脉灌注化疗(hepatic artery infusion chemotherapy,HAIC)已用于治疗中晚期肝癌。HAIC联合应用分子靶向药物和(或)免疫检查点抑制剂,取得了令人鼓舞的成果。该文介绍了TACE和HAIC的理论基础、发展史及研究进展,分析比较二者的疗效和不良反应,以期为中晚期肝癌患者选择治疗时机及治疗方案提供参考。At present,transcatheter arterial chemoembolization(TACE)is a common treatment for advanced unresectable hepatocellular carcinoma(HCC).In recent years,hepatic artery infusion chemotherapy(HAIC)with oxaliplatin plus fluorouracil and leucovorin(FOLFOX)regimen has been used in the treatment of advanced HCC in China.HAIC in combination with molecular targeted drugs and/or immune checkpoint inhibitors has yielded encouraging results.This paper aims to describe the theoretical basis,development history and research progress of TACE and HAIC,to analyze and compare the efficacy and adverse events of TACE and HAIC,so as to provide a reference for the choice of treatment timing and therapeutic regimen for patients with advanced HCC.

关 键 词：肝细胞癌 经导管动脉化疗栓塞术 肝动脉灌注化疗 分子靶向药物治疗 

分 类 号：R735.7[医药卫生—肿瘤]